Review Article
Should We Consider Patients with Coexistent Hepatitis B or C Infection for Orthotopic Heart Transplantation?
Table 1
Studies correlating HBV/HCV infection and clinical outcomes after cardiac transplantation.
| | Author | Country | Cohort size | Follow-up | Measure | Outcome |
| | Haji et al., 2006 [10] | USA |
HBV group
Donor HBcAb+ ()
Recipient HBcAb+ ()
Control group () | 1 year | HBV seropositivity with CAV | CAV risk increased when HBV seropositivity was found in either donor or recipient |
| | Lee et al., 2011 [11] | USA | = 20,687
HCV+ group ()
HCV− group ( = 20,224) | 5.6 years | HCV positivity (hepatitis C Ab +) and survival | Higher mortality in HCV+ group (most of the deaths due to CAV) |
| |
Fagiuoli et al., 2001 [12] | Italy | | years | Prevalence, clinical
course of HBV and HCV in HTX recipients | Significant proportion of patients with HBV and/or HCV infection developed chronic liver disease |
| | Hosenpud et al., 2000 [13] | USA | | days | Outcomes in patients who are HBsAg+ prior to HTX | Chronic liver disease is more common in HBsAg+ patients |
|
|
HBV: hepatitis B virus, CAV: cardiac allograft vasculopathy, HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, HTX: heart transplantation, HBcAb: hepatitis B core antibody.
|
